Join the Oncology Voice Network. Join for Free
Season 2, Episode 20: Exploring The ProFound with John Lepore

Season 2, Episode 20: Exploring The ProFound with John Lepore


Share This Article


Summary

Join host Michael Pietrack on The Pharmaverse Podcast as he talks with John Lepore, CEO of ProFound Therapeutics, about leadership, career pivots, and the future of pharmaceutical innovation. Discover how passion, mentorship, and strategic partnerships drive breakthrough therapies and impact patient care.

In this episode:

👉Explore ProFound Therapeutics' innovative approach to discovering novel proteins and therapies.

👉Learn leadership lessons for small companies vs. large corporations.

👉Gain insights into career management, mentorship, and taking calculated risks.

👉Hear inspiring stories on how science, focus, and urgency shape breakthroughs.

👉Understand the importance of company culture, accountability, and collaboration in the pharmaceutical industry.

📌 Don’t forget to subscribe for more insights from leaders shaping the future of pharma and healthcare innovation.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN